The incidence of non-hematologic AEs, such as fever, thyroid dysfunction, pneumonia, fatigue, increased ALT/AST, gastroenteritis, and rash showed no significant difference between Sintilimab group and Pembrolizumab group. The gene discussed is GPT; the disease is susceptibility to pneumonia measurement.